IKT
Inhibikase Therapeutics, Inc.
Latest Form 4:Purchase$3.0MbySands Capital Life Sciences Pulse Fund II, L.P. (10% Owner) · filed Nov 24, 2025
Inhibikase Therapeutics, Inc. (IKT) has 6 SEC Form 4 filings (6 transaction rows) in the rolling window, disclosed by 1 distinct insider. Most recent filing: Jul 31, 2026.
- Industry:Biotechnology
- CEO:Mark T. Iwicki
- Employees:35
- HQ:Wilmington, DE, US
- IPO:2020-12-23
Insider Buying
$3.0M
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Unique Insiders
1
in the rolling window
Market Cap
$336.3M
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
Sands Capital Life Sciences Pulse Fund II, L.P.First filing | 10% Owner | Purchase | 2,068,965 | $3.0M | Nov 24 | SEC ↗ |
Related companies
Inhibikase Therapeutics, Inc. is in the Healthcare sector.